Flora Growth Corp. Enters into Cannabinoid Science

Flora Growth Corp. (NASDAQ: FLGC) recently announced the next stage of its development with the creation of Flora Pharma and the execution of an agreement to begin scientific clinical trials globally. Flora Pharma’s formation follows the acknowledgment and commitment by the management team and board of directors to move ahead with applied research in medical cannabis in order to become a leader in the discovery, development, manufacturing, and commercialization of novel, phytocannabinoid-based prescription medicines, and nutraceutical products to address a broad range of diseases.

The company also signed an agreement to begin scientific clinical trials on the use of to treat fibromyalgia and chronic pain, with the primary research sites for the global effort located in the U.S. and U.K. “Our team is incredibly excited to announce our entry into cannabinoid science,” president and CEO Luis Merchan was quoted in a recent article. “Commercial harvests are well underway, and it is now that we’re able to turn our attention to what …

Full story available on Benzinga.com

More Flora Growth Corp. Enters into Cannabinoid Science